The GLP-1 Gold Rush:
Who Will Support the Millions of Clients Pharma Is Creating?

The GLP-1 gold rush is real. Analysts are still debating the eventual ceiling, but not the direction of travel. Morgan Stanley now models the global GLP-1 market for diabetes and obesity at roughly $190 billion by 2035. J.P. Morgan sees the broader incretin market at $200 billion by 2030. McKinsey says sales could reach $100 billion by 2030.

Manufacturers are preparing accordingly. Eli Lilly announced it had increased investment at its Indiana manufacturing site to $9 billion, while Novo Nordisk's annual report highlighted more than DKK 80 billion invested in new active-pharmaceutical-ingredient facilities. Big Pharma is building capacity because demand is no longer theoretical.

But that is not the most important question for practitioners. The more urgent question is what happens after the prescription conversation begins. Pharma is scaling GLP-1 access. Access alone does not create education, structure, or long-term support.

The Prescription Is Not the Program

Real-world data is the corrective to simplistic GLP-1 narratives. In a large JAMA Network Open cohort study, the one-year discontinuation rate was 46.5% for patients with type 2 diabetes and 64.8% for those without it. Gastrointestinal adverse effects remain common, especially during dose escalation — Wegovy labeling reports GI adverse reactions in 73% of treated adults in weight-reduction trials.

A Cleveland Clinic study found that patients treated in ordinary clinical practice lost considerably less weight on average than participants in randomized clinical trials, largely because of discontinuation and lower maintenance doses. At one year, average body-weight reduction was 11.9% among those who stayed on treatment, versus 3.6% among those who discontinued early. For context, the STEP 1 semaglutide trial reported a 14.9% reduction at 68 weeks — the gap matters because it changes client expectations, and unrealistic expectations erode adherence.

Maintenance is another underappreciated reality. In the STEP 1 extension study, participants regained roughly two-thirds of prior weight loss within one year of stopping semaglutide, with cardiometabolic improvements trending back toward baseline. Meanwhile, KFF found that 54% of adults who had taken GLP-1s said the drugs were difficult to afford. Medication access is therefore only one part of the journey. The rest involves persistence, tolerability, affordability, and long-term habit support.

The Support Gap Is Where Professionals Need to Pay Attention

This is where the opportunity becomes clear. The best professional guidance is not saying "medication is enough." It is saying the opposite. A 2025 multi-organization nutrition advisory — from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society — argues that GLP-1 outcomes are improved when pharmacotherapy is paired with structured nutrition guidance and broader lifestyle support.

The advisory calls out eight priorities: baseline nutrition assessment, GI side-effect management, prevention of micronutrient deficiencies, adequate protein intake, strength training to preserve lean mass, and support across sleep, stress, activity, and social connection. A 2025 Frontiers review reaches a similar conclusion: GLP-1s produce substantial weight loss, but resistance training helps preserve lean mass and improves the odds of durable results.

Even clients who are prescribed GLP-1s ask questions their prescriber may not have time to address during a clinical appointment: What should I expect? How do I eat when my appetite disappears? Why has progress slowed? What happens if I stop? The support workload is real — and it belongs to a team, not just one clinician.

The Right Role for Non-Prescribers

The opportunity, however, is not to blur professional scope. Medication management belongs to the prescribing clinician and licensed medical team. The National Board for Health and Wellness Coaching states plainly that coaches do not diagnose, prescribe, interpret medical data, or provide treatment. The Academy of Nutrition and Dietetics makes a parallel distinction: individualized medical nutrition therapy is the work of registered dietitian nutritionists.

For many professionals, the appropriate GLP-1 role is education, motivation, general nutrition support within scope, behavior-change coaching, follow-up systems, and referral awareness. A support professional should know that persistent vomiting, dehydration symptoms, severe abdominal pain, or suspected pancreatitis are not "coaching problems" — they are reasons to direct the client back to the prescribing team promptly.

What Professionals Should Be Building Right Now

Professionals who expect this wave to continue should be building fluency across at least nine areas. Without a shared framework, clinics and wellness businesses tend to drift into one of two failure modes: they say too little and leave clients unsupported, or they say too much and drift outside scope. Training solves both problems.

• GLP-1 literacy — so teams understand use cases, limits, and common client expectations
• Scope-aware language — so staff know what they can and cannot say in client-facing conversations
• Client-education frameworks — that normalize follow-up and set realistic expectations
• Protein and nutrition-support basics — within appropriate professional scope
• Hydration and GI side-effect support language — to reduce friction during the adaptation phase
• Lean-mass preservation awareness — strength training and movement guidance that supports outcomes
• Referral triggers and red-flag escalation — clear handoff criteria back to the prescribing team
• Follow-up systems — that track adherence, tolerance, and questions over time
• Team communication standards — so every staff member delivers a consistent client experience

That is not overreach. It is basic preparedness for a category expanding faster than most practice systems were built to handle.

Why Certification Matters for GLP-1 Client Support

Markets scale quickly. Teams usually do not. Without a shared framework, training tends to be informal, inconsistent, and unevenly applied. When a coach explains things differently than the front-desk coordinator, and the coordinator explains things differently than the nurse, the client experience fragments — and fragmented experiences erode trust and retention.

Certification creates common language, common boundaries, consistent education, and clear handoff points between support professionals and licensed clinicians. That is precisely the kind of infrastructure current professional guidance is asking for: comprehensive care, shared decision-making, better adherence support, and practical nutrition and lifestyle systems around the medication journey.

The EMPOWERD GLP-1 CERTIFICATION™ is positioned for this moment: helping professionals understand the GLP-1 client journey, communicate within scope, and build structured support systems around education, nutrition, follow-up, and implementation. It is not a prescribing credential. It is a client-support education system for the teams already at the center of these conversations.